| Ytd | -48.96% | |
| 1y | -50.13% |
| Open | 3.91 | Prev Close | 3.84 | Low | 3.71 | High | 3.97 | Mkt Cap | 4.99M |
| Vol | 14.76K | Avg Vol | 128.39K | EPS | -8.94 | P/E | N/A | Forward P/E | -159.83 |
| Beta | 1.50 | Short Ratio | 0.14 | Inst. Own | 0.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-01 | 50-d Avg | 5.63 | 200-d Avg | 6.87 | 1yr Est | 30.00 |
ADXN News
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics
Gainers Autonomix Medical (NASDAQ:AMIX) stock moved upwards by 142.1% to $13.0 during Monday's
Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular sess
Gainers Picard Medical (AMEX:PMI) stock rose 40.2% to $4.5 during Friday's after-market session
Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares moved upwards by 74.6% to $0.75 during Friday
Gainers Werewolf Therapeutics (NASDAQ:HOWL) stock moved upwards by 77.1% to $0.76 during Thursday&#
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday'
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-mark
Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript
Addex Therapeutics (NASDAQ:ADXN) reported first-quarter financial results on Thursday. The transcrip
Companies Reporting Before The Bell • TD Synnex (NYSE:SNX) is projected to report quarterly earnings
Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(1.53) per share. This is a 15.04 per
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (
Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage bio
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026 - Addex Therapeutics (S
Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call Transcript
Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(1.50) per share. This is a 9.49 perc
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive a
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics
Addex Therapeutics Ltd. Sponsored ADR (NASDAQ: ADXN - Get Free Report) saw a large decrease in short
Addex Therapeutics Ltd. Sponsored ADR (NASDAQ: ADXN - Get Free Report) was the target of a large gro
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutic
Aditxt (NASDAQ: ADTX - Get Free Report) and Addex Therapeutics (NASDAQ: ADXN - Get Free Report) are
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeuti
Up to $3,300,000American Depositary Shares Representing Ordinary SharesWe have entered into an At T
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript
Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(1.50) per share. This is a 45.85 per
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutic
Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2025 Earnings Call October 1, 2025 10:00 AM EDT Company Par
Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(2.90) per share. This is a 127.37 pe
Cash position of CHF 2.3 million at end of H1 2025 GABAB PAM chronic cough candidate demonstrated ro
Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage bi